cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Alaunos Therapeutics Inc
15 own
5 watching
Current Price
$1.07
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
17.13M
52-Week High
52-Week High
9.75000
52-Week Low
52-Week Low
0.60000
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization17.13M
icon52-Week High9.75000
icon52-Week Low0.60000
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Alaunos Therapeutics Inc do?
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Read More
How much money does Alaunos Therapeutics Inc make?
News & Events about Alaunos Therapeutics Inc.
Globe Newswire
1 year ago
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster presentation for its lead non-viral ...
Ticker Report
1 year ago
Alaunos Therapeutics, Inc. (NASDAQ:TCRT Get Rating) Investment analysts at Jefferies Financial Group issued their FY2027 earnings estimates for Alaunos Therapeutics in a research note issued on Tuesday, March 7th. Jefferies Financial Group analyst C. Howerton forecasts that the ...
Globe Newswire
1 year ago
Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR TCR discovery platformIncreasing patient enrollment to advance TCR-T Library Program towards Phase 2 using high value TCRs targeting common hotspot ...
Globe Newswire
1 year ago
HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing of its underwritten public offering of approximately24,228,719 shares of its common stock for gross ...
Globe Newswire
1 year ago
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets. Following the ...
Frequently Asked Questions
Frequently Asked Questions
What is Alaunos Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Alaunos Therapeutics Inc shares?
plus_minus_icon
How can I buy Alaunos Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Alaunos Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Alaunos Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Alaunos Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Alaunos Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Alaunos Therapeutics Inc?
plus_minus_icon
What percentage is Alaunos Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Alaunos Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.07
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00